Evidence map›Paper›PMID 28885007›Full record

ArticleACS chemical neuroscience2017

Stereoselective Differences between the Reinforcing and Motivational Effects of Cathinone-Derived 4-Methylmethcathinone (Mephedrone) In Self-Administering Rats.

Helene L Philogene-Khalid, Steven J Simmons, Sunil Nayak, Rose M Martorana, Shu H Su, Yohanka Caro, Brona Ranieri, Kathryn DiFurio, Lili Mo, Taylor A Gentile and 4 more

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Helene L Philogene-KhalidDepartment of Pharmacology, Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania 19140, United States.
Steven J SimmonsCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania 19140, United States.ORCID 0000-0002-6982-4740
Sunil NayakDepartment of Pharmacology, Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania 19140, United States.
Rose M MartoranaCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania 19140, United States.
Shu H SuCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania 19140, United States.
Yohanka CaroCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania 19140, United States.
Brona RanieriCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania 19140, United States.
Kathryn DiFurioCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania 19140, United States.
Lili MoCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania 19140, United States.
Taylor A GentileCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania 19140, United States.
Ali MuradCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania 19140, United States.
Allen B ReitzFox Chase Chemical Diversity Center Inc. , Doylestown, Pennsylvania 18902, United States.
John W MuschampCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania 19140, United States.
Scott M RawlsDepartment of Pharmacology, Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania 19140, United States.
Temple University · USFox Chase Chemical Diversity Center · US

Funding

Pilot Projects Core (PPC)P30DA013429 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI Munir Gunes Kutlu · 2000 to 2026
$34.6M
TRAINING PROGRAM: DRUGS OF ABUSE RELATED NEUROPEPTIDEST32DA007237 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI ELLEN M UNTERWALD · 1988 to 2026
$10.6M
Psychoactive bath salts and the glutamate systemR01DA039139 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI RAWLS, SCOTT M. · 2015 to 2019
$1.8M
NIDA NIH HHS P30 DA013429NIDA NIH HHS R01 DA039139NIDA NIH HHS T32 DA007237
6 · The paper itself

Abstract

Mephedrone (4-methylmethcathinone (4-MMC)) (MEPH) is a new psychoactive substance (NPS) of the synthetic cathinone class. MEPH has a chiral center and exists as two enantiomers (R-,S-MEPH), yet stereospecific effects of MEPH have not been extensively investigated in preclinical assays. Because significant behavioral and neurochemical differences can exist between enantiomers, probing effects of stereochemistry on biological activity enables separation of adverse and therapeutic effects. Our prior work showed that R-MEPH, relative to S-MEPH, produced greater locomotor activation, place preference, and facilitation of brain reward thresholds in rodents. The present study sought to determine if MEPH enantiomers display stereospecific reward and reinforcement in rat self-administration assays. In Experiment 1, rats were trained to self-administer racemic MEPH (0.50 mg/kg/inf), and dose substitution effects of R-MEPH (0.50 mg/kg/inf) and S-MEPH (0.25, 0.50, 2.00 mg/kg/inf) were examined. In Experiment 2, separate rats were trained to self-administer R-MEPH (0.25, 0.50, 2.00 mg/kg/inf) or S-MEPH (0.25, 0.50, 2.00 mg/kg/inf) and were thereafter evaluated under progressive-ratio access conditions. Within this cohort, 50 kHz ultrasonic vocalizations (USVs) were recorded to measure potential differences in subjective positive affect associated with MEPH enantiomer self-administration. We identified enantiomer- and dose-dependent effects on infusions earned during self-administration following acquisition of racemic MEPH, with greatest infusions under low-effort, fixed-ratio 1 access conditions from low-dose S-MEPH self-administration. When taxed with progressive-ratio access conditions, rats trained to self-administer R-MEPH showed higher break points than those of rats trained to self-administer S-MEPH. Additionally, R-MEPH elicited greatest rates of 50 kHz USVs compared to S-MEPH. Taken together, these data suggest that the R-enantiomer of MEPH is primarily responsible for the rewarding, reinforcing, and motivational properties of racemic MEPH, which increases our understanding of stereospecific preferences pertaining to MEPH abuse.

Indexed as

RewardAnimalsBehavior, AnimalDose-Response Relationship, DrugMaleMethamphetamineMotivationRatsRats, Sprague-DawleySelf AdministrationStereoisomerismStructure-Activity RelationshipTreatment OutcomemephedroneMethamphetamineAddictionmephedroneself-administrationstereoselectivesynthetic cathinoneultrasonic vocalizations

Identifiers

PMID28885007
PMCPMC5792057
OpenAlexW2753196575

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.